🇺🇸 FDA
Pipeline program

RBP-6300

RB-UK-11-0017

Phase 2 small_molecule completed

Quick answer

RBP-6300 for Opioid Related Disorder is a Phase 2 program (small_molecule) at Indivior Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Indivior Pharmaceuticals
Indication
Opioid Related Disorder
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials